PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemicadverseeffects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Oral minoxidil is considered a safe and effective treatment for hair loss at low dosages, with minimal cardiac risks. Users report positive results, though some experience side effects like increased heart rate and skin changes, and consulting a doctor is advised.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemiceffects.
Concerns about the potential systemiceffects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
The regimen includes using a diluted 5.5% Minoxidil / 0.025% Finasteride solution daily, microneedling weekly, and ketoconazole shampoo twice a week to minimize systemic exposure while maximizing scalp DHT reduction. The goal is to achieve hair regrowth with minimal side effects.